Autolus Therapeutics (AUTL) Retained Earnings (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Retained Earnings for 9 consecutive years, with $1.6 billion the latest figure, recorded in Q4 2025.

• Quarterly Retained Earnings rose 0.93% year-over-year to $1.6 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 billion (up 0.93% YoY) and the FY2025 annual result came in at $1.6 billion, up 0.93% from the prior year.
• Retained Earnings held at $1.6 billion in Q4 2025 per AUTL's latest filing, from $1.6 billion in the prior quarter.
• Over the last five years, Retained Earnings for AUTL reached as high as $1.6 billion in Q4 2025 and fell as low as $716.5 million in Q1 2021.
• A 5-year average of $1.2 billion and a median of $1.0 billion in 2023 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2024 — Retained Earnings jumped 52.68% — and 2025, when it gained 0.93%.
• Year by year, Retained Earnings stood at $843.1 million in 2021, then gained by 19.51% to $1.0 billion in 2022, then advanced by 1.12% to $1.0 billion in 2023, then jumped by 52.67% to $1.6 billion in 2024, then gained by 0.93% to $1.6 billion in 2025.
• According to Business Quant data, Retained Earnings over the past three periods registered $1.6 billion, $1.6 billion, and $1.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.